
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Gustave Roussy-cancer research institute in Europe, focusing on patient care, research, and teaching-announced it has selected, and signed a five-year commitment to, TrialMaster electronic data capture (EDC) technology from global provider of clinical data management technology, OmniComm Systems, Inc. TrialMaster will support Gustave Roussy-sponsored clinical trials in oncology.
Read the full release






